ストックスクリーナーアプリを入手
529.24
1.42%
7.40
アフターアワーズ：
528.02
-1.22
-0.23%
前日終値:
$521.84
開ける：
$518.25
24時間の取引高:
951.32K
Relative Volume:
0.74
時価総額：
$53.25B
収益：
$14.09B
当期純損益:
$4.50B
株価収益率:
13.47
EPS:
39.28
ネットキャッシュフロー:
$2.96B
1週間 パフォーマンス:
+7.30%
1か月 パフォーマンス:
-7.82%
6か月 パフォーマンス:
-27.63%
1年 パフォーマンス:
-48.44%
1日の値動き範囲:
$514.98
$529.55
1週間の範囲:
$494.42
$529.99
52週間の値動き範囲:
$476.49
$1,211.20
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
名前
Regeneron Pharmaceuticals Inc
セクター
電話
(914) 847-7000
住所
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
REGN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-30 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | アップグレード | Citigroup | Neutral → Buy |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-02-05 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | ダウングレード | UBS | Buy → Neutral |
| 2024-12-10 | 再開されました | BofA Securities | Underperform |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Neutral |
| 2024-09-24 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | 開始されました | Bernstein | Outperform |
| 2024-01-12 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-11-03 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | 繰り返されました | Oppenheimer | Perform |
| 2023-06-28 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | アップグレード | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | アップグレード | Jefferies | Hold → Buy |
| 2023-03-23 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | アップグレード | Cowen | Market Perform → Outperform |
| 2023-01-20 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-10-26 | ダウングレード | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-09-09 | アップグレード | Jefferies | Underperform → Hold |
| 2022-09-09 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-06-06 | 開始されました | Jefferies | Underperform |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2022-01-05 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-01-03 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | 再開されました | Wells Fargo | Overweight |
| 2021-12-07 | 再開されました | Cowen | Market Perform |
| 2021-12-06 | 開始されました | Goldman | Buy |
| 2021-11-19 | 再開されました | BMO Capital Markets | Outperform |
| 2021-11-05 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2021-06-29 | 開始されました | H.C. Wainwright | Buy |
| 2021-01-25 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | アップグレード | The Benchmark Company | Hold → Buy |
| 2021-01-08 | アップグレード | Citigroup | Neutral → Buy |
| 2020-10-05 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2020-07-09 | アップグレード | SunTrust | Hold → Buy |
| 2020-05-26 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-04-17 | アップグレード | The Benchmark Company | Hold → Buy |
| 2020-04-08 | 開始されました | The Benchmark Company | Hold |
| 2020-03-31 | 開始されました | Wolfe Research | Peer Perform |
| 2020-02-27 | 開始されました | Barclays | Overweight |
| 2020-02-26 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | アップグレード | Jefferies | Hold → Buy |
| 2020-02-11 | アップグレード | Argus | Hold → Buy |
| 2019-12-24 | 開始されました | Raymond James | Mkt Perform |
| 2019-12-16 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-12-13 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | 開始されました | SunTrust | Hold |
| 2019-11-07 | アップグレード | Citigroup | Neutral → Buy |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-09-23 | アップグレード | Guggenheim | Neutral → Buy |
すべてを表示
Regeneron Pharmaceuticals Inc (REGN) 最新ニュース
New England Research & Management Inc. Invests $384,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron (REGN) Chosen as Backup Bidder in 23andMe Asset Sale | - GuruFocus
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Handelsbanken Fonder AB - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Fifth Third Bancorp - MarketBeat
1,547 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bought by Harbor Capital Advisors Inc. - MarketBeat
Regeneron’s SWOT analysis: stock faces eylea challenges, pipeline potential - Investing.com
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Miracle Mile Advisors LLC - MarketBeat
Tounjian Advisory Partners LLC Invests $662,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Research Analysts Offer Predictions for REGN FY2026 Earnings - MarketBeat
23andMe co-founder Anne Wojcicki has bought back the company - NewsBytes
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Wedmont Private Capital - MarketBeat
23andMe's founder Anne Wojcicki wins bid for bankrupt DNA testing firm - MSN
Atwood & Palmer Inc. Has $26.62 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Anne Wojcicki to buy back 23andMe and its data for $305 million - MSN
Regeneron requests bundling ban after trial win - Global Competition Review
Former 23andMe CEO wins bidding war against Regeneron - FirstWord
23andMe's founder Anne Wojcicki wins bid for DNA testing firm - MSN
23andMe founder buys back genetic testing company in second auction - Financial Times
23andMe’s founder Anne Wojcicki wins bid for bankrupt DNA testing firm - New York Post
23andMe’s founder Anne Wojcicki wins bid for DNA testing firm - The Mighty 790 KFGO
Anne Wojcicki wins back 23andMe in bankruptcy court sale - The Business Journals
Regeneron (REGN) Chosen as Backup Bidder in 23andMe Asset Sale | REGN Stock News - GuruFocus
23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process - Benzinga
Avanza Fonder AB Has $5.57 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
JPMorgan Calls the Selloff Excessive, Trims Regeneron Pharmaceuticals, Inc. (REGN) Price Target - MSN
Smithbridge Asset Management Inc. DE Invests $3.41 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
NorthCrest Asset Manangement LLC Has $7.55 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
2,141 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bought by RMR Wealth Builders - MarketBeat
Pallas Capital Advisors LLC Takes $426,000 Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Breakthroughs in Autoimmune Treatment Propel Interleukin - openPR.com
Consumer sentiment, Regeneron meeting, Apple WWDC: What to Watch - Yahoo Finance
Is This Stock a Buy After Acquiring a Potential Zepbound Competitor? - MSN
Regeneron Genetics Center Selects Olink® Explore HT for Landmark Proteomics Study of 200,000 Patient Samples - BioSpace
Greenwood Capital Associates LLC Invests $5.35 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Monitoring Eylea Biosimilar Closely Following Innovative Setbacks - insights.citeline.com
When (REGN) Moves Investors should Listen - news.stocktradersdaily.com
Merit Financial Group LLC Buys 761 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Analysts Set Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Target Price at $836.48 - MarketBeat
Regeneron Licenses Weight Loss Drug and Shares Muscle Preservation Study Data as Bluebird Bio Goes Private - geneonline.com
TB Alternative Assets Ltd. Acquires New Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MSN
Assenagon Asset Management S.A. Has $305.31 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
What’s Regeneron’s $256 Million Plan for 23andMe? - River Journal Online
Lake Hills Wealth Management LLC Purchases Shares of 616 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
23andMe Privacy Reviewer’s Law Firm Discloses Work for Regeneron - Bloomberg Law News
23andMe lawsuit: 27 states, including Illinois, Wisconsin, sue to block sale of personal genetic data to Regeneron Pharmaceuticals - ABC7 Chicago
Shareholders Filed a Lawsuit Against Regeneron Pharmaceuticals for Misleading Pricing Practices - TradingView
States sue to block the sale of 23andMe personal genetic data - NBC10 Philadelphia
Regeneron Pharma Shares Rise Over 3% After Key Signal - Benzinga
Regeneron Pharmaceuticals Inc (REGN) 財務データ
収益
当期純利益
現金流量
EPS
1.09%
1.51%
大文字化:
|
ボリューム (24 時間):